View Post

Genomic Assays Advance Personalized Care in Early-Stage Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Caroline Seymour eFrom: onclive.com The collective results of the MINDACT and TAILORx trials provided a better directive in terms of whether or not to give endocrine therapy alone or in combination with chemotherapy for patients with node-negative, early-stage hormone receptor (HR)–positive, HER2-negative breast cancer, said Mariana Chavez Mac Gregor, MD, MSc. “In patients who have early-stage HR-positive, HER2-negative disease, …

View Post

Multiple Oncotype DX Study Presentations at the 2018 San Antonio Breast Cancer Symposium Reinforce Real-world Value of the Oncotype DX Breast Recurrence Score® Test in Patients Regardless of Age or Race

In Clinical Trials by Barbara Jacoby

News provided by: WCG/Genomic Health From: prnewswire.com Genomic Health, Inc. (NASDAQ: GHDX) today announced results from multiple Oncotype DX Breast Recurrence Score® (RS) presentations at the 2018 San Antonio Breast Cancer Symposium® (SABCS), reinforcing the value of the Oncotype DX® test in optimizing treatment and outcomes in patients with both node-negative and node-positive early-stage breast cancer. Among the data presented …